A new study reports that baseline dual-layer spectral detector CT measurements combined with clinical factors—such as B symptoms and Ki-67—can predict which lymphoma patients will progress first and experience shorter progression-free survival after first-line treatment. Spectral CT offers tissue characterization beyond conventional attenuation-based imaging. The approach suggests a potential imaging biomarker framework that could complement pathology and clinical staging to identify higher-risk patients earlier in the care pathway. The study emphasizes integrating imaging physics features with tumor biology markers. If validated prospectively, this kind of radiomics-style model could influence treatment selection, trial enrichment, and early escalation strategies in lymphoma where outcomes vary widely even within standard regimens.